share_log

Jefferies Downgrades Fusion Pharmaceuticals to Hold, Raises Price Target to $21

Benzinga ·  Mar 19 10:55

Jefferies analyst Andrew Tsai downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Hold and raises the price target from $10 to $21.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment